Global Anorexiants Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Catecholamines Anorexiants and Serotonin Anorexiants

By Route of Administration;

Oral and Subcutaneous

By Distribution Channel;

Online Pharmacies and Retail Pharmacies

By End User;

Institutional Sales, Hospitals, Clinics, Retail Sales, Online pharmacies, and Mail Order Pharmacies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn293996578 Published Date: June, 2025 Updated Date: July, 2025

Anorexiants Market Overview

Anorexiants Market (USD Million)

Anorexiants Market was valued at USD 1,030.53 million in the year 2024. The size of this market is expected to increase to USD 1,470.48 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.2%.


Global Anorexiants Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 5.2 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.2 %
Market Size (2024)USD 1,030.53 Million
Market Size (2031)USD 1,470.48 Million
Market ConcentrationMedium
Report Pages320
1,030.53
2024
1,470.48
2031

Major Players

  • Novo Nordisk A/S
  • Boehringer Ingelheim International GmbH
  • Arena Pharmaceuticals, Inc
  • Eisai Co., Ltd
  • Orexigen Therapeutics, Inc
  • Vivus, Inc
  • Rhythm Pharmaceuticals, Inc
  • Nalpropion Pharmaceuticals, Inc
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Anorexiants Market

Fragmented - Highly competitive market without dominant players


The Anorexiants Market is experiencing steady growth due to the increasing prevalence of obesity and related metabolic conditions. With nearly 45% of adults classified as overweight or obese, the demand for pharmacological weight management tools such as anorexiants is expanding. These appetite suppressants are now integral to clinical weight loss programs worldwide.

Increasing Preference for Non-Invasive Weight Management
Consumers are increasingly opting for non-invasive weight loss therapies, with about 38% favoring prescription anorexiants over surgical procedures. This trend is prompting pharmaceutical companies to develop more targeted and effective appetite suppressants that align with patient needs and safety standards.

Technological Advancements in Drug Formulations
Improved drug delivery systems and advanced formulations have significantly boosted the therapeutic performance of anorexiants. Over 30% of all prescriptions now involve modified-release technologies or combination drugs, which enhance patient adherence and enable prolonged appetite suppression.

Psychological Wellness and Behavioral Integration
The integration of behavioral therapies with pharmacological treatment is becoming increasingly common. More than 25% of anorexiant interventions now include psychological support, reflecting a growing emphasis on holistic weight loss strategies that address both physiological and mental health aspects.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Route of Administration
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Anorexiants Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Obesity Prevalence Globally
        2. Rising Awareness on Weight Management
        3. Advancements in Drug Formulations
        4. Growing Healthcare Expenditure
      2. Restraints
        1. Potential Side Effects Concerns
        2. High Cost of Medications
        3. Stringent Regulatory Approvals
        4. Availability of Alternative Treatments
      3. Opportunities
        1. Expanding Emerging Markets
        2. Innovative Drug Development
        3. Rising Telehealth Adoption
        4. Strategic Collaborations and Partnerships
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Anorexiants Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Catecholamines Anorexiants
      2. Serotonin Anorexiants
    2. Anorexiants Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Oral
      2. Subcutaneous
    3. Anorexiants Market, By Distribution Channel, 2021 - 2031 (USD Million)

      1. Online Pharmacies

      2. Retail Pharmacies

    4. Anorexiants Market, By End User, 2021 - 2031 (USD Million)
      1. Institutional sales
      2. Hospitals
      3. Clinics
      4. Retail sales
      5. Online pharmacies
      6. Mail Order Pharmacies
    5. Anorexiants Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novo Nordisk A/S
      2. Boehringer Ingelheim International GmbH
      3. Arena Pharmaceuticals, Inc
      4. Eisai Co., Ltd
      5. Orexigen Therapeutics, Inc
      6. Vivus, Inc
      7. Rhythm Pharmaceuticals, Inc
      8. Nalpropion Pharmaceuticals, Inc
      9. GlaxoSmithKline plc
      10. Takeda Pharmaceutical Company Limited
  7. Analyst view
  8. Future Outlook of the Market